Clinical Trial: A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old

U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT06953583) titled 'A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old' on April 11.

Brief Summary: In this study, researchers will learn more about the effects and safety of BIIB141, also known as omaveloxolone or SKYCLARYS(R). This drug has been approved, or made available for doctors to prescribe, for people with Friedreich's Ataxia (FA) who are at least 16 years old. But, it is not yet available for children and teens with FA who are younger than 16 years old. The main objective of this study is to learn how BIIB141 works in the body and about its saf...